Clinical Efficacy of Anlotinib Combined with PD-1 Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer
[Objective]To investigate the efficacy of anlotinib combined with programmed death-1(PD-1)inhibitor in the treatment of patients with advanced non-small cell lung cancer(NSCLC).[Methods]A retrospective analysis was con-ducted on the clinical data of 90 NSCLC patients,who were divided into the control group(n=30,treated with anlotin-ib)and the observation group(n=60,treated with anlotinib combined with PD-1 inhibitor)based on different treatment methods.The short-term efficacy,survival,and drug safety of the two groups were compared.[Results]After treatment,the objective response rate(ORR)in the observation group was 11.67％(7/60),and the disease control rate(DCR)was 60.00％(36/60),which were higher than those in the control group[ORR:6.67％(2/30),DCR:33.33％(10/30)],with statistically significant differences(P＜0.05).The median progression-free survival(PFS)in the observation group was 10 months,and the median overall survival(OS)was 13 months.Both PFS and OS in the observation group were longer than those in the control group(median PFS:7 months,median OS:11 months),with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).[Conclusion]The combination of anlotinib and PD-1 inhibitors in the treatment of advanced NSCLC can effectively improve the short-term efficacy and extend the survival time of patients.
Carcinoma,Non-Small-Cell Lung/DTProgrammed Cell Death 1 Receptor/TUTreat-ment Outcome
NETL
NSTL
万方数据
